Compare WRBY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WRBY | EVO |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 568.6M |
| IPO Year | 2021 | 2007 |
| Metric | WRBY | EVO |
|---|---|---|
| Price | $27.49 | $1.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $30.46 | $4.23 |
| AVG Volume (30 Days) | ★ 3.0M | 143.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.88 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $871,905,000.00 | N/A |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | $17.05 | $20.51 |
| P/E Ratio | $468.00 | ★ N/A |
| Revenue Growth | ★ 13.04 | N/A |
| 52 Week Low | $14.96 | $1.50 |
| 52 Week High | $31.00 | $4.27 |
| Indicator | WRBY | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 46.64 |
| Support Level | $21.67 | $1.50 |
| Resistance Level | $30.51 | $1.97 |
| Average True Range (ATR) | 1.61 | 0.05 |
| MACD | 0.52 | 0.02 |
| Stochastic Oscillator | 91.35 | 76.00 |
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.